Tevogen Bio Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$21.6MTTM through 30 Jun 2026
Free Cash Flow -$11.6MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
243.1%ROE
Balance Sheet Health
Debt / Equity-0.91x
Current Ratio0.22x
Net Debt$5.5M
Cash & Equivalents$0
Quality Metrics
Altman Z-Score-58.43
Piotroski F-Score2 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
Diluted EPS-$6.29TTMFY2025: $-7.91
Dividend
No dividend
Capital Allocation
R&D Spend$11.6M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.